Our Services
Medical Information
Helpful Resources
Published on: 9/16/2026
Stopping venlafaxine suddenly is rarely life-threatening, but its short half-life makes discontinuation symptoms especially common and intense, including dizziness, "brain zaps," nausea, flu-like aches, insomnia, irritability, and crying spells that can begin within a day or two of a missed dose. Symptoms usually fade over one to three weeks, though severe cases can bring confusion, worsening depression, agitation, or suicidal thoughts that need urgent medical attention, and a slow taper guided by your prescriber greatly lowers the risk. Dose, how long you have taken it, other medications, and whether you are pregnant all change how risky an abrupt stop may be, so there are several important factors to consider before assuming you are fine. See below to understand the full picture, including warning signs that mean you should not wait to get help. Because withdrawal effects and a relapse of depression can feel nearly identical, a free, instant, online symptom check can help you sort out what is likely driving how you feel right now and what to do next. Take a few minutes to answer a few questions and get clear, personalized guidance on your next steps before your symptoms escalate.
Last reviewed for medical accuracy: 09/15/2025
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) often prescribed for depression, anxiety or panic disorders. If you stop taking venlafaxine suddenly, you can experience a discontinuation (withdrawal) syndrome that ranges from mild to severe. Understanding the risks and how to manage them can help you navigate this safely.
Why Sudden Stopping Matters
Venlafaxine affects brain chemicals (serotonin and norepinephrine). When you take it daily, your body adapts. If you quit “cold turkey,” these chemicals drop suddenly, and your nervous system struggles to rebalance. That imbalance leads to withdrawal symptoms—sometimes called “discontinuation syndrome.”
Common Withdrawal Symptoms
You may notice symptoms within 1–7 days of your last dose. They can last 1–4 weeks or longer if the taper is too fast. Common signs include:
Are Withdrawal Symptoms Dangerous?
Most people experience discomfort rather than life-threatening issues. However, risks include:
While the withdrawal syndrome itself isn’t usually fatal, its effects can indirectly threaten your safety or mental health. It’s critical to recognize severe signs early and get help.
Risk Factors for More Severe Withdrawal
Certain factors can make discontinuation worse:
Managing and Minimizing Withdrawal Risks
Taper Gradually
• Work with your doctor to devise a taper schedule.
• A common approach is reducing the dose by 10–25% every 1–3 weeks, depending on tolerance.
• For very sensitive individuals, smaller reductions over several months may be needed.
Monitor Symptoms Closely
• Keep a daily log of any new or worsening symptoms.
• Share this log with your prescribing professional.
Supportive Self-Care
• Stay hydrated and eat balanced meals.
• Practice good sleep hygiene: regular bedtime, limit screens before bed.
• Use relaxation techniques: deep breathing, gentle yoga or meditation.
Consider Temporary Symptomatic Relief
• Over-the-counter pain relievers for headaches or muscle aches.
• Anti-nausea remedies (under a pharmacist’s guidance).
• Avoid alcohol and recreational drugs—they can worsen symptoms.
Seek Professional Guidance
• Speak to your prescribing doctor before making any changes.
• If withdrawal feels unmanageable, a slower taper or a brief dose increase may help.
Quick Symptom Check
If you’re unsure whether your symptoms relate to venlafaxine withdrawal or something more serious, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
When to Seek Immediate Help
Contact emergency services or go to the nearest hospital if you experience:
Always mention your recent change in venlafaxine dosing so clinicians can provide the best care.
Long-Term Outlook
With a well-planned taper and adequate support, most people recover fully from discontinuation symptoms in a few weeks to months. Some may experience mild “rebound” anxiety or sleep issues—these often respond to non-drug strategies or a brief consultation with a mental-health professional.
Key Takeaways
If you’re considering stopping venlafaxine or are already experiencing withdrawal, talk with your prescribing doctor or a mental-health professional before making any changes. For any life-threatening or serious concerns, always seek emergency care right away.
(References)
* Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother. 2005 Apr;39(4):748-52. doi: 10.1345/aph.1E564. Epub 2005 Feb 22. PMID: 15728327.
* Sabljić V, Ružić K, Rakun R. Venlafaxine withdrawal syndrome. Psychiatr Danub. 2011 Mar;23(1):117-9. PMID: 21448114.
* Garrett AR, Hawley JS. SSRI-associated bruxism: A systematic review of published case reports. Neurol Clin Pract. 2018 Apr;8(2):135-141. doi: 10.1212/CPJ.0000000000000433. PMID: 29708207; PMCID: PMC5914744.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283-306. doi: 10.1159/000506868. Epub 2020 Apr 7. PMID: 32259826.
* Meyer G, Erb A, Michel B, Hingray C, Duval F, Javelot H. [Tinnitus and venlafaxine discontinuation syndrome]. Therapie. 2021 Sep-Oct;76(5):483-486. doi: 10.1016/j.therap.2020.06.009. Epub 2020 Jun 26. PMID: 32646690.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Redecker TM, Jeung-Maarse H, Brandt C. Panic disorder in epilepsy. Epilepsy Behav Rep. 2024;25:100646. doi: 10.1016/j.ebr.2024.100646. Epub 2024 Jan 9. PMID: 38299123; PMCID: PMC10828572.
* Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024 Jul;11(7):526-535. doi: 10.1016/S2215-0366(24)00133-0. Epub 2024 Jun 5. PMID: 38851198.
* Moreland P, Gaffney B, Lanham JS. Migraine Headache Prophylaxis. Am Fam Physician. 2025 May;111(5):443-450. PMID: 40378325.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.